A new paradigm in allogenic stem cells
A new benchmark:
Cell lines established in the year 2000 from a single source
ReoStem is a unique, replicable, clinical-stage technology platform for the generation of allogenic stem cells. It covers all stages of cell culture from derivation, expansion, and establishment of cell lines to the preparation of ready-to-use allogenic stem cell products.
ReoStem technology produces cell lines which are capable of differentiating into almost all the cell types of the body. The suppression of immunogenic genes make universality an important feature of these cell lines. Greater than 90% viability is routinely achieved in the ready-to-use format when kept under temperature-controlled conditions for more than 10 years. There is no contamination with any animal products, bacteria or fungi. Microarray data show that ReoStem cells are genetically stable.
The resultant products have genomic stability and universal acceptability.
CELL CULTUREMETHODOLOGY
The cell lines were derived from a single, expendable fertilized ovum in the year 2000 from a regular IVF cycle undertaken with due consent. This novel technology was subsequently patented and published.
UNIQUE PROFILE of ReoStem
ReoStem is an allogenic stem cell platform. It combines the following features:
Ethically derived from a
pre-morula
fertilized ovum
Ethically derived from a
pre-morula
fertilized ovum
The cell lines are ethically derived from a very early stage spare, fertilized ovum from an IVF cycle after due consent.
No animal product
contamination
No animal product
contamination
No animal products are used either in the primary culture media or as growth factors. There are no feeder cells. The cells are grown in suspension and their purity is maintained.
Allogenic
stem cell lines
Allogenic
stem cell lines
ReoStem technology has two cell lines- one is predominantly neuronal and the other is predominantly non-neuronal.
Cell lines from
a single source
Cell lines from
a single source
Cell lines currently in use derived from a single source in the year 2000 and have maintained full cell viability and stability
Chromosomally
stable
Chromosomally
stable
The cell lines demonstrate long-term chromosomal stability based on over 19 years of expansion and observation since the year 2000.
Universally
acceptable
Universally
acceptable
The technology preserves the purity of the cell lines and maintains the absence of surface antigens. Thus, the cells need not be matched to the recipient and are applicable universally.
No immunosuppression
required
No immunosuppression
required
The cells do not trigger an immune reaction due to the absence of HLA antigens on the cell surface. Therefore, no immune-suppressants are required to be co-administered with the cells/ treatment.
No teratoma
or tumour formation
No teratoma
or tumour formation
Safety and efficacy studies and longitudinal observation over a time frame of over 15 years has confirmed safety of the technology. No adverse events, teratomas or tumours have been observed.
Ready-to-use
products
Ready-to-use
products
The products are available in pre-packaged form ready for clinical use without the need for any further processing.
Long
shelf life
Long
shelf life
The ready-to-use product has a shelf life of 10 years when stored under specified temperature conditions.
UNDERSTANDING
ReoStem TECHNOLOGY
ReoStem platform has derived its cell lines from a single, expendable fertilized ovum taken from a natural IVF cycle with full and informed consent of the donor.
The cells are cultured in an animal product-free media in suspension. The number of cells greatly increase after incubation.
Expansion and Controlled differentiation
Post incubation, the cells are expanded and selectively primed to create two cell lines, enriched for neuronal and non-neuronal precursors, respectively. Uniquely, ReoStem permits incubation and expansion in a cyclic process.
Preparation of ready to use products.
These cells can either be stored or re-incubated. The cells are stored at -18°C to -22°C. The cells are centrifuged and re-suspended in clinical grade normal saline. This is the ready to use product.
Storage of ready-to-use Products.
The ready to use product should be stored at -18°C to -22°C. Its viability is maintained for more than 10 years.
The end use is for clinical application. The product needs to be thawed before use.
